The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Abstract Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known. Here we describe the real‐world use and efficacy of pomalidomide in a Danish, nationwide c...

Full description

Bibliographic Details
Main Authors: Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg, Emil Hermansen, Søren Thorgaard Bønløkke, Katrine Nielsen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Annette Juul Vangsted
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:eJHaem
Subjects:
immunomodulatory agent
myeloma
therapy
Online Access:https://doi.org/10.1002/jha2.774

Internet

https://doi.org/10.1002/jha2.774

Similar Items